Menu

In the Spotlight: Focus in on High-Content Analysis

Find out how combining high sample throughput with multiparametric image and multivariate data analysis enables the detection of even subtle phenotypic changes with this poster from The Scientist and PerkinElmer!

Sep 1, 2018
The Scientist Creative Services Team

High-Content Analysis (HCA) merges the benefits of high-throughput automation and unbiased analysis with microscopic imaging. This powerful - and now highly accessible - technique allows researchers, whether in small academic or large commercial labs to collect and quantify reproducible multiparametric cellular data. HCA has expanded into all corners of life science since its traditional beginnings in drug discovery; HCA techniques are now used widely and in a diverse range of scientific research areas including oncology, neuroscience, infectious disease, developmental biology, and toxicology, to name just a few. HCA can be applied across multiple scales from quantification of subcellular protein distribution through to analyzing the organization of 3D organoids.

Download this poster from The Scientist and PerkinElmer to discover how the combination of high sample throughput with multiparametric image and multivariate data analysis enables the detection of even subtle phenotypic changes that isn’t possible with traditional laboratory techniques.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.